Company Description
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide.
It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer.
The company’s lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn’s disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass.
In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an Keytruda product.
Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.
| Country | Luxembourg |
| Founded | 2013 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 999 |
| CEO | Robert Wessman |
Contact Details
Address: 9, Rue de Bitbourg Luxembourg, 1273 Luxembourg | |
| Website | alvotech.com |
Stock Details
| Ticker Symbol | ALVO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001898416 |
| CUSIP Number | L01800108 |
| ISIN Number | LU2458332611 |
| Employer ID | 98-1629342 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Robert Wessman | Chief Executive Officer, Founder and Executive Chairman |
| Faysal Kalmoua | Chief Operating Officer and Director |
| Joel Morales | Chief Financial Officer |
| Giedrius Zunda | Chief Technical Officer |
| Joseph E. McClellan | Chief Scientific Officer |
| Benedikt Stefansson | Vice President of Investor Relations and Global Communications |
| Tanya Zharov | General Counsel |
| Jenny Sif Steingrimsdottir | Vice President of People and Culture |
| Anil Okay | Chief Commercial Officer |
| Ming Li | Chief Strategy Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 27, 2025 | 20-F | Annual and transition report of foreign private issuers |
| Mar 27, 2025 | 6-K | Report of foreign issuer |
| Mar 27, 2025 | 6-K | Report of foreign issuer |
| Mar 26, 2025 | 6-K | Report of foreign issuer |
| Mar 20, 2025 | 6-K | Report of foreign issuer |
| Mar 18, 2025 | 6-K | Report of foreign issuer |
| Feb 24, 2025 | 6-K | Report of foreign issuer |
| Feb 18, 2025 | 6-K | Report of foreign issuer |
| Jan 27, 2025 | 6-K | Report of foreign issuer |
| Dec 23, 2024 | 6-K | Report of foreign issuer |